Overview
| Product name | Recombinant SARS-COV-2 Spike RBD Protein |
|---|
| Catalog No. | RP02332 |
|---|
| Description | Recombinant SARS-COV-2 SARS-COV-2 Spike RBD Protein is produced by Expi293 expression system. The target protein is expressed with sequence (Arg319-Asn532) of SARS-COV-2 SARS-COV-2 Spike RBD fused with hFc tag and Avi at the C-terminal. |
|---|
| Purity | > 95% by Tris-Bis PAGE;> 95% by SEC-HPLC |
|---|
| Endotoxin | < 1 EU/μg of the protein by LAL method. |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
|---|
| Species | SARS-COV-2 |
|---|
| Calculated MW | 51.7 kDa |
|---|
Product information
| Synonym | S protein RBD; Spike glycoprotein Receptor-binding domain; S glycoprotein RBD; Spike protein RBD |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | C-hFc&Avi |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
